A NEW IMAGING AGENT AS MARKER OF RENAL FUNCTION

ERGANEO



20 Novembre 2020

Partager sur facebook Partager sur twitter Partager sur linkedin Partager sur google+

Fields

Biology / Medical

Sectors

Health

Several causes lead to Chronic kidney diseases (CKD) increased incidence. CKD generate renal fibrosis, responsible for chronic kidney failure, a major public health issue. There are limitations to renal function evaluation and fibrosis treatment : lack of precise and non invasive tools to evaluate renal function and antifibrotic drugs efficacy. Our solution is to use MRI imaging agent as marker of renal function. It could be used both as an imaging marker to assist in the diagnosis and monitoring of chronic renal pathologies related to fibrosis, and as a preclinical and clinical research tool for the development of an antifibrotic agent, as an alternative to the monitoring of biomarkers requiring cumbersome biopsies.

Applications:

  • Renal fibrosis diagnostic
  • Renal function Evaluation and follow up
  • Drug efficacy evaluation

Competitive advantages:

  • Better precision
  • Non invasive evaluation
  • Better care
  • Monitoring new therapies

Keywords: Imaging agent, Renal fibrosis, Renal function evaluation, Drug efficacy testing

Download the offer Download the offer

Newsletter